CN107510710A - A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue - Google Patents
A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue Download PDFInfo
- Publication number
- CN107510710A CN107510710A CN201710946065.9A CN201710946065A CN107510710A CN 107510710 A CN107510710 A CN 107510710A CN 201710946065 A CN201710946065 A CN 201710946065A CN 107510710 A CN107510710 A CN 107510710A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- glycyrrhiza
- concentration
- polyamide
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000202807 Glycyrrhiza Species 0.000 title claims abstract description 52
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 48
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 9
- 239000003112 inhibitor Substances 0.000 title claims description 5
- 239000011347 resin Substances 0.000 claims abstract description 49
- 229920005989 resin Polymers 0.000 claims abstract description 49
- 229930003944 flavone Natural products 0.000 claims abstract description 38
- 235000011949 flavones Nutrition 0.000 claims abstract description 38
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 36
- 238000000605 extraction Methods 0.000 claims abstract description 34
- 239000004952 Polyamide Substances 0.000 claims abstract description 32
- 229920002647 polyamide Polymers 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 27
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 24
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002131 composite material Substances 0.000 claims abstract description 17
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 196
- 239000000284 extract Substances 0.000 claims description 63
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 32
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 32
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 25
- 235000005513 chalcones Nutrition 0.000 claims description 25
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 25
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 claims description 22
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 claims description 22
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 claims description 22
- 238000011068 loading method Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 235000011477 liquorice Nutrition 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 13
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 12
- 230000014759 maintenance of location Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- HJGURBGBPIKRER-UHFFFAOYSA-N Licoflavone A Chemical compound C1=C(O)C(CC=C(C)C)=CC(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 HJGURBGBPIKRER-UHFFFAOYSA-N 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 8
- NRUOYYDQBWDRKE-UHFFFAOYSA-N Kanzonol D Natural products C1=C(O)C(CC=C(C)C)=CC(C=2OC3=CC(O)=CC=C3C(=O)C=2)=C1 NRUOYYDQBWDRKE-UHFFFAOYSA-N 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- GLDVIKFETPAZNV-UHFFFAOYSA-N Licoflavone B Chemical compound C1=C(O)C(CC=C(C)C)=CC(C=2OC3=CC(O)=C(CC=C(C)C)C=C3C(=O)C=2)=C1 GLDVIKFETPAZNV-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 2
- 229940069445 licorice extract Drugs 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 19
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract description 11
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract description 11
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract description 11
- 235000019410 glycyrrhizin Nutrition 0.000 abstract description 11
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract description 10
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 238000000746 purification Methods 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 abstract description 8
- 239000001685 glycyrrhizic acid Substances 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 239000002904 solvent Substances 0.000 abstract description 7
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract description 5
- 229960002632 acarbose Drugs 0.000 abstract description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 231100000753 hepatic injury Toxicity 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 239000003472 antidiabetic agent Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 35
- 229930003935 flavonoid Natural products 0.000 description 27
- 235000017173 flavonoids Nutrition 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 150000002215 flavonoids Chemical class 0.000 description 26
- 238000010828 elution Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 16
- 150000002213 flavones Chemical class 0.000 description 14
- 235000017443 Hedysarum boreale Nutrition 0.000 description 13
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 13
- 229930194248 Licoflavone Natural products 0.000 description 13
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 13
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000013375 chromatographic separation Methods 0.000 description 11
- 238000011097 chromatography purification Methods 0.000 description 11
- -1 flavone compound Chemical class 0.000 description 11
- 238000004611 spectroscopical analysis Methods 0.000 description 11
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 10
- 238000011835 investigation Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- DRDRYGIIYOPBBZ-XBXARRHUSA-N Licochalcone B Natural products COC1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1 DRDRYGIIYOPBBZ-XBXARRHUSA-N 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- COLMVFWKLOZOOP-UHFFFAOYSA-N Glabrone Chemical compound OC1=CC=C2C(=O)C(C3=CC=C4OC(C=CC4=C3O)(C)C)=COC2=C1 COLMVFWKLOZOOP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000007087 Apium graveolens Species 0.000 description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 3
- 235000010591 Appio Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- WBDNTJSRHDSPSR-UHFFFAOYSA-N Licochalcone C Natural products C1=CC(O)=C(CC=C(C)C)C(OC)=C1C=CC(=O)C1=CC=C(O)C=C1 WBDNTJSRHDSPSR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 3
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 3
- 235000008718 isoliquiritigenin Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- RETRVWFVEFCGOK-RMKNXTFCSA-N (e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one Chemical compound COC1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C(CC=C(C)C)=C1 RETRVWFVEFCGOK-RMKNXTFCSA-N 0.000 description 2
- WBDNTJSRHDSPSR-KPKJPENVSA-N (e)-3-[4-hydroxy-2-methoxy-3-(3-methylbut-2-enyl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound C1=CC(O)=C(CC=C(C)C)C(OC)=C1\C=C\C(=O)C1=CC=C(O)C=C1 WBDNTJSRHDSPSR-KPKJPENVSA-N 0.000 description 2
- SWPKMTGYQGHLJS-RNVIBTMRSA-N (e)-3-[4-hydroxy-2-methoxy-5-[(2s)-3-methylbut-3-en-2-yl]phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound COC1=CC(O)=C([C@@H](C)C(C)=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 SWPKMTGYQGHLJS-RNVIBTMRSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- RETRVWFVEFCGOK-UHFFFAOYSA-N Licochalcone D Natural products COC1=C(O)C(O)=CC=C1C=CC(=O)C1=CC=C(O)C(CC=C(C)C)=C1 RETRVWFVEFCGOK-UHFFFAOYSA-N 0.000 description 2
- SWPKMTGYQGHLJS-AWEZNQCLSA-N Licochalcone E Natural products COc1cc(O)c(cc1C=CC(=O)c2ccc(O)cc2)[C@@H](C)C(=C)C SWPKMTGYQGHLJS-AWEZNQCLSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 210000002403 aortic endothelial cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 2
- 229940093767 glabridin Drugs 0.000 description 2
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 2
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000183712 Cerinthe major Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MVAUGMLUJKTORM-UHFFFAOYSA-N Licoricidin Natural products COc1cc2OCC(Cc2cc1CC=C(C)C)c3ccc(O)c(CC=C(C)C)c3O MVAUGMLUJKTORM-UHFFFAOYSA-N 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229930187586 licochalcone Natural products 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- GBRZTUJCDFSIHM-KRWDZBQOSA-N licoricidin Chemical compound C1([C@@H]2COC=3C=C(O)C(CC=C(C)C)=C(C=3C2)OC)=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-KRWDZBQOSA-N 0.000 description 1
- GBRZTUJCDFSIHM-UHFFFAOYSA-N licorisoflavan B Natural products C1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC1C1=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000009719 polyimide resin Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to pharmaceutical technology field; one kind is provided and uses composite adsorption method of purification; (more than 50% is accounted for based on macroreticular resin); it is aided with polyamide, the composite adsorbing material that MCI one or two mix in varing proportions; absorption, purifying and acquisition component are clear and definite from the Glycyrrhiza uralensisFisch residue after extraction glycyrrhizic acid; structure understands; active principle content is high; the method of the good Glycyrrhiza uralensisFisch residue general flavone of activity and its in regulation blood glucose, protection hepatic injury, regulation blood fat, the medical usage for suppressing tumour growth etc..The various sorbing material Combination Designs of the present invention are reasonable, and the technological operation of adsorption and purification is simple and easy to do；Solvent is safe to use, environmentally friendly, economical.Glycyrrhiza uralensisFisch residue general flavone has obvious inhibitory action to the two important target spots of α glucuroides and PTP1B for preventing and treating diabetes B, particularly higher than clinical hypoglycemic drug acarbose to the inhibitory action intensity of α glucuroides more than 10 times.
Description
Technical field：
The present invention relates to pharmaceutical technology field, is related to a kind of Glycyrrhiza uralensisFisch residue using composite adsorption method after glycyrrhizic acid is extracted
The enrichment method and medical usage of the diabetes B target spot inhibitor of middle enrichment high-purity, and in particular to a kind of sweet from Ural
The side of glycyrrhiza total flavonoid is extracted in Glycyrrhiza uralensisFisch residue after the radix glycyrrhizae extraction glycyrrhizic acid not of the same race such as grass, glycyrrhiza glabra, swollen fruit Radix
Method and its application in terms of health food, food additives, medicine or pharmaceutical raw material is prepared.
Background technology：
Radix glycyrrhizae, also known as state is old, well-informed, Herba Hedyotis cantonensis, lantern, honeywort etc., be pulse family Papillionoideae herbaceos perennial, be
A kind of conventional Chinese medicine.So far, isolate to obtain more than 300 kinds of flavone compound from the root and cauline leaf of radix glycyrrhizae and its spread out
Biology, these flavone compounds almost cover most of mother nucleus structure of flavones, especially with chalcone, isoflavones, flavones
(alcohol), flavanone content are more.Flavone compound in radix glycyrrhizae has extensive pharmacological activity, including hypoglycemic, antioxygen
Change, antitumor, anti-inflammatory, antibacterial, liver protection, the effect to reproductive system, antiulcer, anti-arrhythmia, antidepression, protection skin etc.
Effect, in addition, radix glycyrrhizae is widely used in field of food as additives such as sweetener and antioxidants.
Glycyrrhiza uralensisFisch residue is the residue that radix glycyrrhizae extracted glycyrrhizic acid, containing abundant Flavonoid substances, be it is a kind of it is valuable can
Resource is recycled, there is extensive prospect of the application and higher economic value.Yang Xiaohui, Zhang Juan et al. pass through separation and chemistry side
Method identifies triterpenes, flavonoids, glycoside, amino acid, organic acid, cumarin and terpene lactone, phenols in Glycyrrhiza uralensisFisch residue
Deng more than ten class organic principles, show that organic principle is with about the same in radix glycyrrhizae in Glycyrrhiza uralensisFisch residue, a beautiful grade, Yang Lin et al. pass through
HPLC is similar to flavones type in radix glycyrrhizae to 13 flavone compound analysis shows Glycyrrhiza uralensisFisch residues, but content has differences, sweet
Licochalcone A R amount is higher than the amount of Licochalcone A in crude drug in careless residue.Kui occurred frequently et al. is faced with solvent method with super
Boundary CO2Abstraction technique produces extract of licorice root with Glycyrrhiza uralensisFisch residue, the results showed that the extract of licorice root instrument that supercritical extraction technique obtains is sweet
Oxalic acid, licoflavone are main component, and gas chromatograph-mass spectrometer identifies 22 kinds of organic compounds, also amino acid in Glycyrrhiza uralensisFisch residue is entered
Go research, detect 18 kinds of amino acid, content is between 0.04-0.79%, wherein there are 8 kinds of amino acid needed by human.
Licoflavone class material is main chemical compositions in Glycyrrhiza uralensisFisch residue, uses ultraviolet spectrophotometry with rutin or radix glycyrrhizae
Glycosides is reference substance, using ultrasonic wave added organic solvent heat reflow method, combined-enzyme method combination alcohol extracting method, Microwave-Assisted Ethanol leaching,
A variety of methods such as alcohol reflux extraction, flash method, supercritical ultrasonics technology, microwave method are carried to the general flavone in Glycyrrhiza uralensisFisch residue
Take, be that parameter is secondary to Extraction solvent, extraction time, Extracting temperature, solid-to-liquid ratio, extraction using flavones yield, content or inhibitory activity
The factor such as number or enzyme amount, pH is investigated, Optimized Extraction Process.Wu Tao et al. use HPLC methods using Licochalcone A as pair
According to the assay method to establishing flavones in Glycyrrhiza uralensisFisch residue, the inspection for licoflavone assay and Related product provides
With reference to.Zhang Xiaoping extracts glycyrrhiza total flavonoid with Glycyrrhiza uralensisFisch residue, has investigated moulding process, the quality standard research of licoflavone capsule
And stability test, general flavone recovery rate is 4.2%, but licoflavone content only 4.02%.Li Xia etc., Min Jie etc. use HPLC
Method determines the content for comparing glabridin in different sources and Different Extraction Method Glycyrrhiza uralensisFisch residue, the results showed that its content and production
Ground, extracting method and Extraction solvent are closely related.
The purification process of licoflavone includes the most frequently used purification process such as ethyl acetate extraction method, recrystallization method, resin
Method and some other purification process such as ultrafiltration and double-aqueous phase system method etc..
Xu Qingping, Shi Zhongfeng et al. are respectively adopted XAD-16, AB-8 macroreticular resin and have carried out optimal separation to licoflavone
Technique is investigated, and has respectively obtained 55.10% and 66.9% glycyrrhiza total flavonoid.The steady-state solution by glycyrrhiza total flavonoid should be avenged et al.
The parameters such as analysis rate compare to tri- kinds of macroporous absorbent resins of D101, Hz-806, AB-8, the results showed that AB-8 type macroreticular resins
Glycyrrhiza total flavonoid can be efficiently separated, purity is more than 50%.Cheap monarch to D101, S-8, DML30, HPD-300,
ADS-7, HPD-100 and HPD450 macroreticular resin find that HPD-300 has preferable adsorption effect more afterwards, and purifying process is upper
Sample concentration 2.0mg/mL, loading flow velocity 2ml/min, applied sample amount 2BV, with 80% ethanol elution, elution flow rate 1.5BV/h, elution
3BV is measured, flavones purity is obtained and improves more than 2 times.Lv Ziming by NKA-9, X-5, HPD500, XAD-8, HPD600, AB-8,
12 kinds of macroreticular resins such as HPD300, ZG300B, D101, S-8, D301, NKA-2 compare, by Static Adsorption and dynamic
Purifying of the selection AB-8 to licoflavone is investigated in absorption, by being investigated to parameters such as sample concentration, applied sample amount, adsorption flow rate, pH,
It is determined that final purifying process, the purity for obtaining glycyrrhiza total flavonoid is 38%, and wherein XAD-8 is expensive to be not suitable on a large scale should
With.Tian Yanfang et al. has carried out technique investigation using entropy assessment to multi-target screening licoflavone, to 12 kinds of macroreticular resin D101,
AB-8, NKA-9, HPD-100, HPD-300, HPD-400, HPD-500, HPD-772, ADS-7, ADS-17, X-5, D301 etc. are set
Fat is with liquiritin, glycyrrhizin glucose celery glucosides, celery sugar isoliquiritin, isoliquiritigenin glucose celery glucosides, isoliquiritin, strange
The rate of recovery of 6 kinds of flavones such as liquiritin compares, and finds the target product quality after X-5 and HPD-100 type macroreticular resins
Fraction is relatively low, and ADS-7 types macroreticular resin has stronger enrichment selectivity to 6 kinds of flavones, does not adsorb other compositions, 6 kinds of gained
The mass fraction of general flavone is 81.59%, but the maximum composition Licochalcone A of content in radix glycyrrhizae is not analyzed.
It is above the representative example for carrying out extraction purification to glycyrrhiza total flavonoid class material using macroreticular resin, its
Middle macroreticular resin includes different models, existing opposed polarity, also there is cheap and expensive, most total flavonoid
The content of material does not reach 80%, even if having obtained 80% content, but does not have to a large amount of composition such as Licochalcone As therein
It is compared explanation, or constituent is unclear.
Jiang Honghong et al. passes through resin NKA-9, HPD-600, HPD-400, D-101, AB-8, HPD- to opposed polarity
After the sorbing material such as 300 and polyamide carries out the comparison of absorption property, extract to combine using organic reagent and adsorb preferable polyamides
General flavone in polyimide resin purifying liquorice, it is determined that optimal purifying process is first with petroleum ether and ethyl acetate extraction, acetic acid second
Polyamide column is crossed after ester layer medicinal extract is water-soluble, loading pH is 5, flow velocity 1ml/min, sample concentration 0.15g/ml, is finally obtained sweet
The purity of careless general flavone is 90.12%.Li Junsong has been carried out pure using polyamide (60-100 mesh) to general flavone in licorice piece
Change, process conditions are radix glycyrrhizae：Polyamide is 2:1, resin blade diameter length ratio is 1：7, the ethanol elutions of column volume 70% are measured with 5 times, finally
Flavones content is 45% in total solid substance.Liu Jia et al. is carried out to 30-60,60-80,80-100, the polyamide of 100-200 mesh specifications
The comparison of absorption property, the specification absorption property of wherein 30-60 mesh is preferable, there is the concentration of general flavone in licoflavone sample
3.087g/L bring up to 5.177g/L.
It is above the representative example for carrying out extraction purification to glycyrrhiza total flavonoid class material using polyamide, wherein
Polyamide includes different specifications, in terms of result it is most do not reach 80% requirement, the purity for reaching 80% be also first
The step of employing organic reagent extraction is extracted, and the application of organic reagent not only increases cost, also result in simultaneously
Pollution.
Patent CN 102526177A are purified using macroreticular resin to the water-soluble and fat-soluble flavones in radix glycyrrhizae,
But the purity of flavones is not after purification mentioned.Patent CN102204950A to Glycyrrhiza uralensisFisch residue alcohol extracting, dilution, cross post absorption,
The technique extraction general flavone such as elution and concentration, but the macroreticular resin model of the patent is defined as D101 and AB-8.Patent
CN1752081A is extracted using ethyl acetate to Glycyrrhiza uralensisFisch residue, high relative to ethanol reagent cost and unfavorable to environment.Specially
Sharp CN1810796A uses to enter containing two or more the organic reagent including ethanol to radix glycyrrhizae or Glycyrrhiza uralensisFisch residue
Row extraction, and purified without column chromatography, purity is not known.
In summary, when total flavonoids substance in Glycyrrhiza uralensisFisch residue is extracted and purified, largely employ except second
Other organic reagents beyond alcohol, unfavorable to environment, content not can determine that, can not ensure that the purity of glycyrrhiza total flavonoid is more than or waited
In 80%, it is important that obtain glycyrrhiza total flavonoid monomer component composition it is unintelligible, also there are no content and the work of monomer flavones
Property measure data, also just without specific medical usage statement.
The content of the invention：
The purpose of the present invention is after the radix glycyrrhizae extraction glycyrrhizic acid not of the same race such as Glycyrrhiza Uralensis, glycyrrhiza glabra, swollen fruit Radix
Glycyrrhiza uralensisFisch residue in extract glycyrrhiza total flavonoid class material method.Various combination of adsorbents are reasonable in design used in the present invention, purifying
Technique is advanced, easy to operation；Solvent is safe to use, environmentally friendly, economical.And Glycyrrhiza uralensisFisch residue general flavone (LRTF) after extraction purification
Content of the content in total extract is equal to or more than 80%, comprising licochalcone A, B, C, D, E and Licoflavone A, B, C,
The flavone compounds such as glabrone, glabridin, glycyrrhizin, isoliquiritigenin, content account for the 75% of general flavone, synchronous through HPLC
After detection and analysis, wherein liquorice chalcone C, licochalcone A, liquorice chalcone E, liquorice chalcone D, Licoflavone A and sweet
Straw colour ketone B total content >=50%, LRTF material compositions are substantially clear and definite.Obtained LRTF has protection hepatic injury, regulation blood fat, suppression
The multiple biological activities such as tumour growth processed, can extensive use in terms of health food, food additives, medicine or pharmaceutical raw material.
LRTF has obvious inhibitory action to the two important target spots of alpha-glucosidase and PTP1B for preventing and treating diabetes B, especially
It is higher than clinical hypoglycemic drug acarbose to the inhibitory action intensity of alpha-glucosidase more than 10 times.
The present invention is achieved through the following technical solutions：
(1) after being crushed to Glycyrrhiza uralensisFisch residue, temperature is heated to reflux with certain concentration of alcohol, solid-liquid ratio, in certain
Under, extract 1-5 times；
Radix glycyrrhizae crushes to a certain extent, can not be too broken.Certain concentration of alcohol refers to 40-90% (V/V) ethanol water, excellent
Elect 60-80% (V/V), solid-liquid ratio 1 as:5-1:50, the temperature being heated to reflux is 60-90 DEG C, extraction time 1-4h, extraction
Number is 1-5 times.
(2) merge extract solution to certain concentration, reclaim ethanol.It is 0.1- that finite concentration, which refers to licorice extract concentration,
5.0mg/mL。
(3) extract solution is added in composite adsorbing material and purified, first wash away impurity with a certain proportion of ethanol water, so
The concentration for improving ethanol afterwards is eluted, and eluent finally is drying to obtain into LRTF.
Described composite adsorbing material (accounts for more than 50%) based on macroreticular resin, be aided with one kind in polyamide, MCI or
Two kinds mix in varing proportions.
When composite adsorbing material is that macroreticular resin is used in mixed way with one kind in polyamide, MCI, both ratios are：
1:1~10:5, preferably 5：1-10：1.
Preferred macroreticular resin-the polyamide compositions of described composite adsorbing material or macroreticular resin-MCI combinations.
When composite adsorbing material is that macroreticular resin is used in mixed way with two kinds in polyamide, MCI, the ratio of its three
For：Macroreticular resin：Polyamide：MCI=10:3:2~5:2:2.
The gradient of described ethanol is：20%~100%, preferably 50-100%.
Extract solution described in step (3) is purified, refers to that extract solution crosses absorption with 0.1-5.0BV/h flow velocity
Resin column, 4-24h is stopped after completing loading；Impurity is washed away with a certain proportion of ethanol water to refer to using 1-20BV 5-50% second
Alcohol (preferably 20-50% ethanol) is cleaned with 0.1-5.0BV/h flow velocity.Improve ethanol concentration carry out elution refer to by
1-30 retention volume of elution is carried out with 0.1-5.0BV/h flow velocitys with 50-100% ethanol (preferably 60-90% ethanol) after removal of impurities；
Resulting eluent LRTF after concentrate drying purity is equal to or more than 80%.
LRTF chemical compositions are speculated by HPLC-MS fragment ion analysis, by a variety of chromatographic separation and purifications and carried out
Physicochemical constant and spectroscopy, LRTF is specified by licochalcone A, B, C, D, E and Licoflavone A, B, C, glabrone, light
25 flavone compound compositions such as licoricidin, glycyrrhizin, isoliquiritigenin, and hypoglycemic external activity test aspect is carried out, it is special
It is not that the diabetes B target spot important to alpha-glucosidase and PTP1B two carries out activity analysis, wherein glycyrrhiza total flavonoid pair
The rejection ability of alpha-glucosidase is higher by more than 10 times than comparison medicine acarbose.
Macroporous resin adsorption resin is the separation material that adsorptivity and molecular sieve principle are combined, and its adsorptivity is due to
Van der Waals force or the result for producing hydrogen bond, water-soluble or big polar compound can first flow out, be washed out after the small material of polarity；It is poly-
Acid amides absorption belongs to Hydrogen Binding Adsorption, and polarity is applicable with apolar substance, it is particularly suited for the flavonoids such as separating phenols
Compound；MCI is a kind of polymeric substrate filler, the same with C18 based on absorption, while MCI is one kind of gel, mainly
The anti-phase and principle of molecular sieve.Flavone compound contains phenolic hydroxyl group, easily forms hydrogen bond, the number of phenolic hydroxyl group, determines flavones
The polarity size of compound, and there is certain acidity.The composite adsorbing material that the present invention uses will be divided based on macroreticular resin
Sugared from the big polarity in material or other impurity have carried out purifying with water first and removed, the glycyrrhizic acid and flavones of least a portion of residual
Then it is enriched with, remove least a portion of glycyrrhizic acid in residual Glycyrrhiza uralensisFisch residue with 30% ethanol afterwards, finally with the ethanol of high concentration
Afford the LRTF of high-purity, the sorbing material technological operation after combination is simple and easy to do；Solvent is safe to use, it is environmentally friendly,
Economy, final high efficiency, it is achieved at low cost the diabetes B target that high-purity is enriched with from the Glycyrrhiza uralensisFisch residue after extraction glycyrrhizic acid
Point inhibitor, makes it be developed into high value added product.Described composite adsorbing material based on macroreticular resin (account for 50% with
On), it is aided with polyamide, MCI one or two mix in varing proportions.Its different effect of the composition of composite adsorbing material is former
Reason is also differed, and the composition of obtained general flavone is also slightly different, but the content of general flavone is more than 80%.
Advantages of the present invention is fairly obvious compared with other methods：1. composite adsorbing material group used in extraction and purge process
Close reasonable in design, the technological operation of purifying is simple and easy to do；Solvent is safe to use, environmentally friendly, economical.2. employ macroreticular resin to be aided with
The composite adsorption method of other sorbing materials composition, content of the content of general flavone in total extract is more than or waited after extraction purification
In 80%, the content in total extract of Licochalcone A is more than or equal to 10%.3. flavonoid compound composition is substantially clear
Chu, there is regulation blood glucose, protection hepatic injury, regulation blood fat, suppress the multiple biological activities such as tumour growth etc., eaten in health care
Can extensive use in terms of product, food additives, medicine or pharmaceutical raw material.In hypoglycemic activity especially alpha-glucosidase and
Diabetes B target spot important PTP1B two has obvious activity inhibition, and particularly glycyrrhiza total flavonoid is to phlorose
The rejection ability of glycosides enzyme is higher by more than 10 times than comparison medicine acarbose.
Brief description of the drawings：
Fig. 1 is the investigation result of sample concentration
Fig. 2 is the investigation result of adsorption flow rate
Fig. 3 is leakage plot
Fig. 4 is the investigation result of removal of impurities elution volume
Fig. 5 is the investigation result of wash-out concentration
Fig. 6 is the investigation result of elution volume
Fig. 7 is the anti-inflammatory activity test result of chalcone A
Fig. 8 is licoflavone effect for reducing blood fat test result
Fig. 9 is the anti-hepatic fibrosis test result of glycyrrhiza total flavonoid.
Embodiment：
Embodiment 1：Extracting liquorice residue is appropriate, adds the ethanol that concentration is 70%, solid-liquid ratio 1:30, it is small in 90 DEG C of extractions 2
When, extract 3 times, merge extract solution, reclaim ethanol.It is 4.0mg/mL to make extract of licorice root solution concentration, then with 1BV/h flow velocity
Cross macroreticular resin：Polyamide=1:1 adsorption resin column, 12h is stopped after completing loading, it is fully adsorbed, with the second of 5BV 50%
Alcohol is cleaned with 2BV/h flow velocity, is then carried out eluting 15 retention volumes with 3BV/h flow velocitys with 80% ethanol, recovery is washed
De- liquid, is dried, and it is 80% to obtain LRTF purity and account for total extract content, and licochalcone A content accounts for total extract content as 10%.Should
With HPLC-MS carry out fragment ion analysis speculate its chemical composition, using a variety of chromatographic separation and purifications and carry out physicochemical constant and
Spectroscopy, its compound group is specified into determining the content of Licochalcone A, and carry out hypoglycemic external activity α-grape
Glycosidase and the important target spots of PTP1B two carry out activity analysis.
Embodiment 2：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 70%, solid-liquid ratio 1:30, extracted 2 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 4.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 1BV/h flow velocity
Fat：Polyamide=5:1 adsorption resin column, 12h is stopped after completing loading, it is fully adsorbed, with the ethanol of 5BV 50% with 2BV/h
Flow velocity cleaned, then with 80% ethanol with 3BV/h flow velocitys carry out elute 15 retention volumes, reclaim eluent, dry,
It is 85% to obtain LRTF contents and account for total extract content, and licochalcone A content accounts for total extract content as 12%.Using HPLC-
MS carries out fragment ion analysis and speculates its chemical composition, using a variety of chromatographic separation and purifications and carries out physicochemical constant and spectroscopy mirror
It is fixed, specify its compound group into, determine the content of Licochalcone A, and carry out hypoglycemic external activity alpha-glucosidase and
Target spot important PTP1B two carries out activity analysis.
Embodiment 3：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 70%, solid-liquid ratio 1:30, extracted 2 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 4.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 1BV/h flow velocity
Fat：Polyamide=10:1 adsorption resin column, 12h is stopped after completing loading, it is fully adsorbed, with the ethanol of 5BV 50% with 2BV/
H flow velocity is cleaned, and is then carried out eluting 15 retention volumes with 3BV/h flow velocitys with 80% ethanol, is reclaimed eluent, do
Dry, it is 90% to obtain LRTF contents and account for total extract content, and licochalcone A content accounts for total extract content as 18%.Using HPLC-
MS carries out fragment ion analysis and speculates its chemical composition, using a variety of chromatographic separation and purifications and carries out physicochemical constant and spectroscopy mirror
It is fixed, its compound group is specified into determining the content of Licochalcone A, and carry out hypoglycemic active determination in vitro and analysis.
Embodiment 4：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 80%, solid-liquid ratio 1:40, extracted 3 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 5.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 2BV/h flow velocity
Fat：MCI=1:1 adsorption resin column, 24h is stopped after completing loading, it is fully adsorbed, with the ethanol of 6BV 50% with 4BV/h's
Flow velocity is cleaned, and is then carried out eluting 20 retention volumes with 5BV/h flow velocitys with 85% ethanol, is reclaimed eluent, dry, obtain
It is 83% to account for total extract content to LRTF contents, and chalcone A content accounts for total extract content as 11%.Using HPLC-MS carry out from
Sub- debris analysis speculates its chemical composition, using a variety of chromatographic separation and purifications and carries out physicochemical constant and spectroscopy, clearly
Its compound group into, determine the content of Licochalcone A, and alpha-glucosidase and PTP1B inhibitory activity are measured and
Analysis.
Embodiment 5：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 80%, solid-liquid ratio 1:40, extracted 3 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 5.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 2BV/h flow velocity
Fat：Polyamide：MCI=5:3:2 adsorption resin columns, 24h is stopped after completing loading, it is fully adsorbed, with the ethanol of 6BV 50%
Cleaned with 4BV/h flow velocity, then carried out eluting 20 retention volumes, recovery elution with 5BV/h flow velocitys with 85% ethanol
Liquid, dry, it is 83% to obtain glycyrrhiza total flavonoid LRTF contents and account for total extract content, and chalcone A accounts for total extract content as 14%.Should
With HPLC-MS carry out fragment ion analysis speculate its chemical composition, using a variety of chromatographic separation and purifications and carry out physicochemical constant and
Spectroscopy, specify its compound group into, determine the content of Licochalcone A, and carry out alpha-glucosidase and PTP1B suppression
Determination of activity and analysis processed.
Embodiment 6：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 80%, solid-liquid ratio 1:40, extracted 3 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 5.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 2BV/h flow velocity
Fat：Polyamide：MCI=10:3:2 adsorption resin columns, 24h is stopped after completing loading, it is fully adsorbed, with the ethanol of 6BV 50%
Cleaned with 4BV/h flow velocity, then carried out eluting 20 retention volumes, recovery elution with 5BV/h flow velocitys with 85% ethanol
Liquid, dry, it is 87% to obtain glycyrrhiza total flavonoid LRTF contents and account for total extract content, and chalcone A content accounts for total extract content and is
15%.Fragment ion analysis is carried out using HPLC-MS and speculates its chemical composition, using a variety of chromatographic separation and purifications and carries out physics and chemistry
Constant and spectroscopy, its compound group is specified into determining the content of Licochalcone A, and carry out hypoglycemic activity measure
With analysis.
Embodiment 7：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 60%, solid-liquid ratio 1:20, extracted 1 hour at 90 DEG C, extraction 2
It is secondary, merge extract solution, reclaim ethanol.It is 3.0mg/mL to make extract of licorice root solution concentration, then crosses macropore with 0.5BV/h flow velocity
Resin：MCI=5:1 adsorption resin column, 6h is stopped after completing loading, it is fully adsorbed, with the ethanol of 3BV 20% with 1BV/h's
Flow velocity is cleaned, and is then carried out eluting 10 retention volumes with 2BV/h flow velocitys with 60% ethanol, is reclaimed eluent, dry, obtain
It is 83% to account for total extract content to glycyrrhiza total flavonoid LRTF contents, and chalcone A content accounts for total extract content as 14%.Using
HPLC-MS carries out fragment ion analysis and speculates its chemical composition, using a variety of chromatographic separation and purifications and carries out physicochemical constant and light
Spectroscopy identify, specify its compound group into, determine the content of Licochalcone A, and carry out hypoglycemic active determination in vitro with point
Analysis.
Embodiment 8：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 80%, solid-liquid ratio 1:40, extracted 3 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 5.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 2BV/h flow velocity
Fat：Polyamide：MCI=5:2:2 adsorption resin columns, 24h is stopped after completing loading, it is fully adsorbed, with the ethanol of 6BV 50%
Cleaned with 4BV/h flow velocity, then carried out eluting 20 retention volumes, recovery elution with 5BV/h flow velocitys with 85% ethanol
Liquid, dry, it is 82% to obtain glycyrrhiza total flavonoid LRTF contents and account for total extract content, and chalcone A content accounts for total extract content and is
16%.Fragment ion analysis is carried out using HPLC-MS and speculates its chemical composition, using a variety of chromatographic separation and purifications and carries out physics and chemistry
Constant and spectroscopy, its compound group is specified into determining the content of Licochalcone A, and carry out hypoglycemic external activity
Measure and analysis.
Embodiment 9：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 70%, solid-liquid ratio 1:25, extracted 3 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 5.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 2BV/h flow velocity
Fat：Polyamide=10:5 adsorption resin columns, 24h is stopped after completing loading, it is fully adsorbed, with the ethanol of 6BV 50% with 4BV/
H flow velocity is cleaned, and is then carried out eluting 20 retention volumes with 5BV/h flow velocitys with 85% ethanol, is reclaimed eluent, do
Dry, it is 81% to obtain glycyrrhiza total flavonoid LRTF contents and account for total extract content, and chalcone A content accounts for total extract content as 13%.Should
With HPLC-MS carry out fragment ion analysis speculate its chemical composition, using a variety of chromatographic separation and purifications and carry out physicochemical constant and
Spectroscopy, specify its compound group into, determine the content of Licochalcone A, and carry out hypoglycemic active determination in vitro and
Analysis.
Embodiment 10：
Extracting liquorice residue is appropriate, adds the ethanol that concentration is 70%, solid-liquid ratio 1:40, extracted 3 hours at 90 DEG C, extraction 3
It is secondary, merge extract solution, reclaim ethanol.It is 5.0mg/mL to make extract of licorice root solution concentration, then crosses macropore tree with 2BV/h flow velocity
Fat：MCI=10:5 adsorption resin columns, 24h is stopped after completing loading, it is fully adsorbed, with the ethanol of 6BV 50% with 4BV/h's
Flow velocity is cleaned, and is then carried out eluting 18 retention volumes with 5BV/h flow velocitys with 85% ethanol, is reclaimed eluent, dry, obtain
It is 83% to account for total extract content to glycyrrhiza total flavonoid LRTF contents, and chalcone A accounts for total extract content as 15%.Using HPLC-MS
Carry out fragment ion analysis and speculate its chemical composition, using a variety of chromatographic separation and purifications and carry out physicochemical constant and spectroscopy mirror
It is fixed, its compound group is specified into determining the content of Licochalcone A, and carry out hypoglycemic active determination in vitro and analysis.
By taking embodiment 1 as an example, experimental result is as follows：
The investigation of sample concentration
Extract of licorice root solution passes through HPD-100 with 4.0mg/mL, 2.0mg/mL, 0.5mg/mL concentration respectively：Polyamide
=1:1 adsorption resin column (600mm × 15mm i.d.), Dynamic Adsorption is carried out with 1BV/h flow velocity.Efflux receives 1 per 3mL
Part, stop loading when outflow concentration is more than the 10% of stoste after testing, record loading volume.As a result Fig. 1 is seen.
Adsorption flow rate is investigated
Extracting liquorice medicinal extract solution crosses HPD-100 with C=4.0mg/mL：Polyamide=5:1 adsorption resin column, respectively with 0.5,
1 and 2BV/h flow velocity carries out Dynamic Adsorption.Efflux receives 1 part per 3mL, stops when outflow concentration is more than the 10% of stoste
Only loading.As a result Fig. 2 is seen.
The investigation of leakage plot
Take HPD-100：Polyamide=1:1 adsorption resin column (600mm × 15mm i.d.), wet method dress post, extracting liquorice medicinal extract
Solution concentration is that 4.0mg/mL sample solution is appropriate, with 1BV/h flow velocity loading, collects efflux, is 1 part per 3ml, is calculated yellow
Ketone concentration ratio.As a result Fig. 3 is seen.
50% ethanol removal of impurities elution volume is investigated
Extracting liquorice medicinal extract solution C=4.0mg/mL solution, HPD-100 is crossed with 1BV/h flow velocity：Polyamide=1:1 inhales
Attached resin column, 4h is stopped after completing loading, treats that it is fully adsorbed, afterwards with enough 50% ethanol elutions, Fractional Collections eluent (with
1BV is counted), result of calculation is shown in Fig. 4.
The investigation of wash-out concentration
Extracting liquorice medicinal extract solution concentration is 4.0mg/mL 4 parts, every part of 42.0mL of load solution, respectively with 1BV/h stream
Speed crosses HPD-100：Polyamide=1:1 adsorption resin column, 4h is stopped after completing loading, it is fully adsorbed, with the second of 5BV 50%
Alcohol is cleaned with 2BV/h flow velocity.60%, 70%, 80% and 90% ethanol is eluted (flow velocity 3BV/h) respectively, elution
To efflux substantially without color, eluent is collected, eluent is dried under reduced pressure to obtain solid content, is dissolved and is settled to 70% ethanol
250mL, measure light absorption value.As a result Fig. 5 is seen.
The investigation of elution volume
Extracting liquorice medicinal extract solution concentration is 4.0mg/mL sample solution 42.0mL, and HPD-100 is crossed with 1BV/h：Polyamide=
1:1 adsorption resin column, 2h is stopped after completing loading, it is fully adsorbed, removed with 5BV50% ethanol with 2BV/h flow velocity elution
It is miscellaneous, eluted with 80% ethanol with 3BV/h flow velocity, 1 part is collected per 1BV eluents, it is yellow with elution volume (V/mL) for abscissa
Ketone concentration is that ordinate does figure, as a result sees Fig. 6.
HPLC-MS is analyzed
Chromatographic column：Agilent HC-C18 (250mm × 4.6mm, 5 μm), mobile phase：0.2% acetic acid water (A), methanol
(B), Detection wavelength：310nm, flow velocity：1mL/min, column temperature：25 DEG C, sample size：10μL.0-10min, 55%A；10-32min,
55%-38%A；32-45min, 38%-30%A；45-60min, 30%-10%A.In this condition using liquorice chalcone C,
Radix glycyrrhizae is looked into and ketone A, liquorice chalcone E, liquorice chalcone D, Licoflavone A and Licoflavone B are analyzed for reference substance, as a result
Show total content >=50%.
Alpha-glucosidase and PTP1B target spot external activities analysis result (alpha-glucosidase positive drug is acarbose,
PTP1B positive drug is sodium vanadate)
Embodiment 9：LRTF and its chalcone A anti-inflammatory activity
High-purity LRTF anti-inflammatory activities：Mouse aortic endothelial cell is carried out using LPS (100ng/mL) different time sections
Stimulate so that VCAM-1 in cell, IL-6 and COX-2 altimeter reach, be subsequently added into be recrystallized to give in high-purity LRTF it is sweet
Careless chalcone A (LA) tests its anti-inflammatory activity and anti-adhesion effect.Add and look into the post-stimulatory mouse aortic endothelial cells of LPS
After your ketone A (LA), the reduction trend of dose dependent is presented in VCAM-1, IL-6 gene expression, while chalcone A inhibits
COX-2 gene expression.Chalcone anti-inflammatory activity test result is shown in Fig. 7.
Embodiment 10：LRTF hypolipidemic activity
By ApoE-/-Knock out mice is divided into model group, the high, medium and low dosage groups of high-purity LRTF (120mg/kg/day,
60mg/kg/day, 30mg/kg/day) and ginkgo leaf positive controls, C57BL/6J mouse are as blank control group.Every group
10 mouse, raising carry out gastric infusion after one week.TC, TG, HDL-C in mice serum, LDL-C water are determined after off-test
It is flat.
Measurement result, which is shown, gives TC in LRTF high dose group mice serums, TG, and LDL-C levels substantially drop compared with model group
It is low, there is significant difference.TG levels are significantly lower than model group in low, middle dose group.HDL-C levels are in 3 dosage groups
Obvious increase.
LRTF effect for reducing blood fat test result such as Fig. 8.
Embodiment 11：LRTF and its chalcone A antitumor activity
High-purity LRTF antitumor activities：Using mtt assay test high-purity LRTF (50,100 μ g/mL) and radix glycyrrhizae
Chalcone A (100,75,50,25,12.5 μm of ol/L) is thin to Human Prostate Cancer Cells PC-3, colon cancer cell HT-29, breast cancer
Born of the same parents MCF-7, people's uterine cancer cells 4 kinds of cells of Hela inhibitory activity.As a result show, high-purity LRTF is 50 and 100 in concentration
μ g/mL, chalcone A plays the role of to suppress growth of cancer cells well in 50,75,100 μm of ol/L, and dose-dependant is presented
Property.Test result is as follows：
Embodiment 12：LRTF effect of anti hepatic fibrosis
Protective effects of the high-purity LRTF to hepatic fibrosis in mice：30 male mice in kunming are randomly divided into 3 groups：It is right
According to group, model group and licoflavone group.Model group and licoflavone group animal intraperitoneal injection N-nitrosodimethylamine 8mg/kg
(2mL/kg), the intraperitoneal injection of control group group three-times-weekly, are administered three weeks with capacity physiological saline.LRTF group gavages are given high-purity
Glycyrrhiza total flavonoid suspension 15mg/kg (0.1mL/10g) is spent, control group and model group gavage give same capacity physiological saline, from
It is administered simultaneously when modeling starts, once a day, successive administration 6 weeks.Last time administration terminates rear fasting 24h, and portal vein takes blood,
Leave and take liver specimens.Venous blood centrifuging and taking serum, liver specimens preserve in different environments according to different detection means, disease
Reason sample is fixed in 10% formalin solution, carries out HE dyeing.Blood sample is centrifuged, and takes supernatant, obtains serum,
It is horizontal to determine AST and ALT in each group serum.
Experimental result arrives：Compared with control group, ALT, ALT content in model group animal blood serum substantially rise (P ＜
0.01).Compared with model group, AST, ALT content in high-purity LRTF animal blood serum have declined (P ＜ 0.05), table
Bright high-purity LRTF has the function that to improve hepar damnification caused by N-nitrosodimethylamine.
Pathology section examination result is shown：Control group liver cell marshalling, orderly, header plot structure and lobuli hepatis knot
Structure is normal.Model group liver cell arrangement disorder, there is the change of balloon sample, be able to observe that obvious hepatic injury.High-purity LRTF groups
Liver cell structure is normal compared with model group, has minimal amount of balloon sample to become.As a result Fig. 9 is seen.
。
Claims (10)
- A kind of 1. method that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue, it is characterised in that comprise the steps of：(1) after being crushed to Glycyrrhiza uralensisFisch residue, with ethanol heating and refluxing extraction 1-5 times；(2) merge extract solution to certain concentration, reclaim ethanol；(3) extract solution is added in composite adsorbing material and purified, first wash away impurity, Ran Houti with a certain proportion of ethanol water The concentration of high ethano is eluted, and eluent finally is drying to obtain into Glycyrrhiza uralensisFisch residue general flavone；Described composite adsorbing material is aided with one or both of polyamide, MCI and mixed based on macroreticular resin.
- 2. the method as described in claim 1, it is characterised in that the concentration of alcohol in the step (1) is that volume ratio is 40- 90% ethanol water, preferably 60-80% (V/V), solid-liquid ratio 1:5-1:50, the temperature being heated to reflux is 60-90 DEG C, extraction Time is 1-4h, and extraction time is 1-5 times.
- 3. the method as described in claim 1, it is characterised in that composite adsorbing material is in macroreticular resin and polyamide, MCI When one kind is used in mixed way, both ratios are：1:1~10:5.
- 4. the method as described in claim 1, it is characterised in that composite adsorbing material is in macroreticular resin and polyamide, MCI Two kinds when being used in mixed way, the ratio of its three is：Macroreticular resin：Polyamide：MCI=10:3:2~5:2:2.
- 5. the method as described in claim 1, it is characterised in that described radix glycyrrhizae is：Glycyrrhiza Uralensis, glycyrrhiza glabra or swollen fruit Radix glycyrrhizae.
- 6. the method as described in claim 1, it is characterised in that the licorice extract concentration described in step (2) is 0.1- 5.0mg/mL。
- 7. the method as described in claim 1, it is characterised in that resin column is crossed with 0.1-5.0BV/h flow velocity, after completing loading 4-24h is stopped, then is cleaned with 1-20BV 5-50% ethanol with 0.1-5.0BV/h flow velocity.
- 8. method as claimed in claim 7, it is characterised in that：With 50-100% ethanol with 0.1-5.0BV/h after removal of impurities Flow velocity carries out eluting 1-30 retention volume.
- 9. the method as described in claim 1-8 any one, it is characterised in that：Resulting LRTF purity is equal to or more than 80%, wherein liquorice chalcone C, licochalcone A, liquorice chalcone E, liquorice chalcone D, Licoflavone A and Licoflavone B Total content >=50%.
- 10. Glycyrrhiza uralensisFisch residue general flavone prepared by the method described in claim 1-9 any one is preparing hypoglycemic, lipid-loweringing, is resisting and swell Application in tumor medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710946065.9A CN107510710A (en) | 2017-10-12 | 2017-10-12 | A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710946065.9A CN107510710A (en) | 2017-10-12 | 2017-10-12 | A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107510710A true CN107510710A (en) | 2017-12-26 |
Family
ID=60726167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710946065.9A Pending CN107510710A (en) | 2017-10-12 | 2017-10-12 | A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107510710A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110292596A (en) * | 2019-08-12 | 2019-10-01 | 沈阳药科大学 | Black raspberry anthocyanin is preparing the application in anti-liver injury medicament or health food |
| CN110950917A (en) * | 2019-11-16 | 2020-04-03 | 浙江大学 | Separation method and application of apiose isoliquiritin |
| CN112457424A (en) * | 2020-12-08 | 2021-03-09 | 中国科学院新疆理化技术研究所 | Preparation method and application of liquorice polysaccharide effective part |
| CN112494478A (en) * | 2020-12-04 | 2021-03-16 | 新疆维吾尔自治区中药民族药研究所 | Composition with anti-inflammatory synergistic effect and application thereof |
| CN113813300A (en) * | 2021-11-02 | 2021-12-21 | 中国科学院新疆理化技术研究所 | Preparation method and application of glycyrrhiza glabra extract |
| CN117100739A (en) * | 2022-05-17 | 2023-11-24 | 北京慧宝源生物技术股份有限公司 | Small molecule composition for negative regulation of Nrf2 signal path and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02204417A (en) * | 1989-02-02 | 1990-08-14 | Maruzen Kasei Co Ltd | Hydrophobic licorice flavonoid preparation |
| CN1544449A (en) * | 2003-11-21 | 2004-11-10 | 中国医药研究开发中心有限公司 | Licorice flavone extracting method from licorice dregs |
| CN102151296A (en) * | 2010-02-11 | 2011-08-17 | 兰州大学 | Method for extracting active ingredients for reducing sugar blood from waste residues of liquorice |
| CN102552239A (en) * | 2011-12-31 | 2012-07-11 | 沈阳药科大学 | Method for preparing anti-inflammatory and anti-tumor active ingredient group from liquorice dregs and application of anti-inflammatory and anti-tumor active ingredient group |
| CN104741094A (en) * | 2015-03-06 | 2015-07-01 | 中山大学惠州研究院 | Composite resin containing polyamide resin and preparation method thereof |
| CN106619798A (en) * | 2016-12-27 | 2017-05-10 | 新疆全泰兴药业科技有限公司 | Extracting process of licorice flavonoid compound |
-
2017
- 2017-10-12 CN CN201710946065.9A patent/CN107510710A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02204417A (en) * | 1989-02-02 | 1990-08-14 | Maruzen Kasei Co Ltd | Hydrophobic licorice flavonoid preparation |
| CN1544449A (en) * | 2003-11-21 | 2004-11-10 | 中国医药研究开发中心有限公司 | Licorice flavone extracting method from licorice dregs |
| CN102151296A (en) * | 2010-02-11 | 2011-08-17 | 兰州大学 | Method for extracting active ingredients for reducing sugar blood from waste residues of liquorice |
| CN102552239A (en) * | 2011-12-31 | 2012-07-11 | 沈阳药科大学 | Method for preparing anti-inflammatory and anti-tumor active ingredient group from liquorice dregs and application of anti-inflammatory and anti-tumor active ingredient group |
| CN104741094A (en) * | 2015-03-06 | 2015-07-01 | 中山大学惠州研究院 | Composite resin containing polyamide resin and preparation method thereof |
| CN106619798A (en) * | 2016-12-27 | 2017-05-10 | 新疆全泰兴药业科技有限公司 | Extracting process of licorice flavonoid compound |
Non-Patent Citations (1)
| Title |
|---|
| 韩龙哲等: "胀果甘草药渣总黄酮和甘草查尔酮A的制备及其体外抗肿瘤活性研究", 《现代药物与临床》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110292596A (en) * | 2019-08-12 | 2019-10-01 | 沈阳药科大学 | Black raspberry anthocyanin is preparing the application in anti-liver injury medicament or health food |
| CN110950917A (en) * | 2019-11-16 | 2020-04-03 | 浙江大学 | Separation method and application of apiose isoliquiritin |
| CN110950917B (en) * | 2019-11-16 | 2021-03-05 | 浙江大学 | Separation method and application of apiose isoliquiritin |
| CN112494478A (en) * | 2020-12-04 | 2021-03-16 | 新疆维吾尔自治区中药民族药研究所 | Composition with anti-inflammatory synergistic effect and application thereof |
| CN112494478B (en) * | 2020-12-04 | 2022-06-07 | 新疆维吾尔自治区中药民族药研究所 | Composition with anti-inflammatory synergistic effect and application thereof |
| CN112457424A (en) * | 2020-12-08 | 2021-03-09 | 中国科学院新疆理化技术研究所 | Preparation method and application of liquorice polysaccharide effective part |
| CN112457424B (en) * | 2020-12-08 | 2022-05-17 | 中国科学院新疆理化技术研究所 | Preparation method and application of liquorice polysaccharide effective part |
| CN113813300A (en) * | 2021-11-02 | 2021-12-21 | 中国科学院新疆理化技术研究所 | Preparation method and application of glycyrrhiza glabra extract |
| CN117100739A (en) * | 2022-05-17 | 2023-11-24 | 北京慧宝源生物技术股份有限公司 | Small molecule composition for negative regulation of Nrf2 signal path and application thereof |
| CN117100739B (en) * | 2022-05-17 | 2024-04-12 | 北京慧宝源生物技术股份有限公司 | Small molecule composition for negative regulation of Nrf2 signal path and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107510710A (en) | A kind of method and medical usage that diabetes B target spot inhibitor is enriched with from Glycyrrhiza uralensisFisch residue | |
| US9089595B2 (en) | Extract of Rehmannia glutinasa Libosch. for reducing blood glucose and lipid levels and treating hematologic diseases, and methods for preparing the same | |
| EP1800685A1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| KR101251589B1 (en) | Method for preparing crude saponin composition enhanced purity and effective saponin contents from platycodon grandiflorum or the extract therefrom | |
| CN103263462B (en) | Desmodium caudatum extractive and extraction method and new application thereof | |
| CN105132172B (en) | A method of preparing tobacco orrisroot Flavonoid substances from orrisroot | |
| CN101485705A (en) | Cooked Panax notoginseng and cooked Panax notoginseng standard extract and application thereof | |
| CN104415070A (en) | Method for separating and purifying total ginsenoside from ginseng | |
| CN102180850A (en) | Dwarf lilyturf tuber medium-high isoflavone compounds, and preparation method and application thereof | |
| CN103554209B (en) | Method for preparing ginsenoside Rg1 from pseudo-ginseng | |
| CN112159451A (en) | Gynostemma pentaphylla saponin extract and preparation method thereof | |
| KR101375483B1 (en) | Ginseng prosapogenin high concentration containing Sanchi ginseng preparation using sonication and process for thereof | |
| CN102764320B (en) | Psychotria sp. extract, and preparation method and antineoplastic application thereof | |
| WO2012088777A1 (en) | Effective part of ginseng, preparing method and use thereof | |
| CN105384784B (en) | The screening of three kinds of antioxidation activity 2,3,5,4'-tetrahydroxyl diphenylethylene-2-O-BETA-D-glucoside class materials, method for separating and preparing in the Qinghai cultivation fleece-flower root | |
| CN106822071B (en) | Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same | |
| CN105801656B (en) | The method that Rg1, Re and Rb1 are purified from arasaponin | |
| US10435384B2 (en) | Method for extracting herbacetin from plants of Rhodiola L | |
| CN102977178B (en) | Triterpenoid saponin compound, extraction method of the triterpenoid saponin compound, and use of the triterpenoid saponin compound in treatment on myocardial ischemia/reperfusion injuries | |
| CN105616470A (en) | Method for extracting and separating saponin and polysaccharide at the same time from brown ginger | |
| CN1887309B (en) | Extraction of effective red sage components for preventing and treating osteoporosis and depression | |
| CN106632197A (en) | Anticancer active site LA-D of Leea crispa van Royen as well as medicinal composition thereof and chemical component separating and identifying method thereof | |
| CN108530505A (en) | A kind of flavonoid glycoside compound and its preparation method and application | |
| CN101401896B (en) | Extracting method of active principle of sarsaparilla | |
| CN109748945A (en) | Four kinds of Gypenoside L and Gypenoside LI acetyl derivatives and its purposes for preparing anti-tumor drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171226 |
|
| RJ01 | Rejection of invention patent application after publication |